当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

Taste and smell perception and quality of life during and after systemic therapy for breast cancer.

Abstract：

PURPOSE:The purpose of the study was to assess self-reported taste and smell perception after chemotherapy in breast cancer patients compared with women without cancer, and to assess whether taste and smell perception is associated with quality of life after the end of chemotherapy. METHODS:We included 135 newly diagnosed breast cancer patients who completed chemotherapy and 114 women without cancer. Questionnaires on taste, smell, and quality of life were completed shortly after and 6 months after chemotherapy (patients) or at two moments with 6 months' time window in between (comparisons). RESULTS:Self-reported taste and smell perception were significantly lower in patients shortly after chemotherapy compared to the comparison group. Most patients recovered 6 months after chemotherapy, although patients who were still receiving trastuzumab then reported a lower taste and smell perception compared to patients who were not. A lower self-reported taste and smell were statistically significantly associated with a worse quality of life, social, emotional, and role functioning shortly after chemotherapy. Six months after chemotherapy, taste and smell were statistically significantly associated with quality of life, social and role functioning, but only in patients receiving trastuzumab. CONCLUSIONS:Most taste and smell alterations recovered within 6 months after the end of chemotherapy for breast cancer, but not for patients receiving trastuzumab. These results highlight the importance of monitoring taste and smell alterations during and after treatment with chemotherapy and trastuzumab, as they may impact quality of life.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

de Vries YC,Boesveldt S,Kelfkens CS,Posthuma EE,van den Berg MMGA,de Kruif JTCM,Haringhuizen A,Sommeijer DW,Buist N,Grosfeld S,de Graaf C,van Laarhoven HWM,Kampman E,Winkels RM

doi

10.1007/s10549-018-4720-3

subject

Has Abstract

pub_date

2018-07-01 00:00:00

pages

27-34

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-018-4720-3

journal_volume

170

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Molecular detection of breast cancer metastasis in sentinel lymph nodes by reverse transcriptase polymerase chain reaction (RT-PCR): identifying, evaluating and establishing multi-marker panels.

    abstract：:The potential advantage of using quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) methodology to detect metastasis in sentinel lymph nodes (SLNs) of breast cancer (BC) patients was evaluated in this prospective study. We measured the expression of relevant gene transcripts in SLNs using an innova...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-011-1710-0

    authors： Wallwiener CW,Wallwiener M,Kurth RR,Röhm C,Neubauer H,Banys MJ,Staebler A,Schönfisch B,Meuer SC,Giese T,Fehm TN

    更新日期：2011-12-01 00:00:00

  • Quality of life in women with recurrent breast cancer.

    abstract：:Although the psychosocial concomitants of early-stage breast cancer have been well-documented, the relationship between cancer recurrence and quality of life remains less clear. We conducted a prospective, longitudinal study in order to clarify the relationship between recurrent cancer and quality of life, and to dete...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006172024218

    authors： Bull AA,Meyerowitz BE,Hart S,Mosconi P,Apolone G,Liberati A

    更新日期：1999-03-01 00:00:00

  • Psychological impact of recall in high-risk breast MRI screening.

    abstract：PURPOSE:To address the widespread concern that false-positive results during breast MRI screening may have adverse psychological effects. METHODS:Impact of Event Scale measurements in 103 high-risk women enrolled in a longitudinal MRI screening study and comparison of subjects with normal results vs. those with prior ...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-008-0140-0

    authors： O'Neill SM,Rubinstein WS,Sener SF,Weissman SM,Newlin AC,West DK,Ecanow DB,Rademaker AW,Edelman RR

    更新日期：2009-05-01 00:00:00

  • Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients.

    abstract：PURPOSE:Breast cancer is a leading cause of cancer deaths in women, but despite steady improvements in therapies, treatment is still suboptimal. Immunotherapy holds promise as a more effective therapy for breast cancer; supporting this, our prior study showed that patients possessing HER2-reactive CD8+ T cells in blood...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-4037-z

    authors： Janssen N,Fortis SP,Speigl L,Haritos C,Sotiriadou NN,Sofopoulos M,Arnogiannaki N,Stavropoulos-Giokas C,Dinou A,Perez S,Pawelec G,Baxevanis CN,Shipp C

    更新日期：2017-01-01 00:00:00

  • Axillary lymph node status of operable breast cancers by combined steroid receptor and HER-2 status: triple positive tumours are more likely lymph node positive.

    abstract：AIMS:To examine the frequency of axillary lymph node (ALN) invasion of operable breast cancers by their combined oestrogen receptor (ER), progesterone receptor (PR) and HER-2 status. METHODS:2227 recently operated cases in one centre were retrieved from the Multidisciplinary Breast Centre database and stratified accor...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9914-7

    authors： Van Calster B,Vanden Bempt I,Drijkoningen M,Pochet N,Cheng J,Van Huffel S,Hendrickx W,Decock J,Huang HJ,Leunen K,Amant F,Berteloot P,Paridaens R,Wildiers H,Van Limbergen E,Weltens C,Timmerman D,Van Gorp T,Smeets A,V

    更新日期：2009-01-01 00:00:00

  • Allelic loss of the PTEN region (10q23) in breast carcinomas of poor pathophenotype.

    abstract：:Loss of heterozygosity (LOH) in loci of the 10q23 region that harbor the PTEN gene and mutations in the sequence of this gene have been found in several primary human tumors including breast carcinomas, suggesting that this gene could be implicated in their pathogenesis. We investigated allelic losses in microsatellit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006273516976

    authors： Garcia JM,Silva JM,Dominguez G,Gonzalez R,Navarro A,Carretero L,Provencio M,España P,Bonilla F

    更新日期：1999-10-01 00:00:00

  • Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry.

    abstract：:The biological subtype of breast cancer influences the selection of systemic therapy. Distinction between luminal A and B cancers depends on consistent assessment of Ki-67, but substantial intra-observer and inter-observer variability exists when immunohistochemistry (IHC) is used. We compared RT-qPCR with IHC in the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-016-3835-7

    authors： Wirtz RM,Sihto H,Isola J,Heikkilä P,Kellokumpu-Lehtinen PL,Auvinen P,Turpeenniemi-Hujanen T,Jyrkkiö S,Lakis S,Schlombs K,Laible M,Weber S,Eidt S,Sahin U,Joensuu H

    更新日期：2016-06-01 00:00:00

  • Loss of BRCA1 expression in sporadic male breast carcinoma.

    abstract：:BRCA1 protein is normally expressed in the nuclei of breast epithelial cells and functions as a negative regulator of the cell cycle. Mutations of BRCA1 gene have been associated with familial breast carcinomas. Although somatic mutations have not been demonstrated in sporadic breast carcinomas, loss of nuclear expres...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1013317909431

    authors： Sun X,Gong Y,Rao MS,Badve S

    更新日期：2002-01-01 00:00:00

  • miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.

    abstract：PURPOSE:Ductal carcinoma in situ (DCIS) is well-known precursor of invasive ductal carcinoma (IDC). Parts of patients show recurrence as DCIS or IDC after local treatment, but there are no established markers predicting relapse. We analyzed changes in miRNA and oncogene expression during DCIS progression/evolution to i...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-019-05192-1

    authors： Lee J,Kim HE,Song YS,Cho EY,Lee A

    更新日期：2019-07-01 00:00:00

  • Fragment c gamma receptor gene polymorphisms and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians.

    abstract：:Previous studies showing the presence of antibodies against tumor-associated antigens in healthy individuals suggest that antibody-dependent cell cytotoxicity (ADCC) might play a role in the development of breast cancer. We hypothesized that functional polymorphisms in fragment c gamma receptor (FcgR) genes were assoc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-010-1109-3

    authors： Iwasaki M,Shimada N,Kasuga Y,Yokoyama S,Onuma H,Nishimura H,Kusama R,Hamada GS,Nishimoto IN,Iyeyasu H,Motola J Jr,Laginha FM,Anzai R,Tsugane S

    更新日期：2011-04-01 00:00:00

  • Histone acetylation decreased by estradiol in the MCF-7 human mammary cancer cell line.

    abstract：:The effect of estradiol (E2) on the [3H]-acetylation of nuclear histones was studied in the MCF-7 human mammary cancer cell line in culture. Cells (approximately 10(8) were incubated with 8 x 10(-6) M [3H]-acetate in the absence (control) or in the presence of estradiol (10(-5)-10(-8) M). After 20 min incubation, the ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01805980

    authors： Pasqualini JR,Mercat P,Giambiagi N

    更新日期：1989-10-01 00:00:00

  • Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.

    abstract：:We have examined a family with a germline BRCA2 mutation in three cases of invasive breast cancer and one case of ductal carcinoma in situ (DCIS). Loss of heterozygosity (LOH) has been demonstrated at the BRCA2 locus in all cases. This result may suggest that the germline mutation in BRCA2 is the initiating step of DC...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-9503-3

    authors： Thomassen M,Kruse TA,Olsen KE,Borg A,Gerdes AM

    更新日期：2004-10-01 00:00:00

  • A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

    abstract：:A dose-response relationship has been suggested for medroxyprogesterone acetate in the treatment of advanced breast cancer. To determine the tolerability and efficacy of increasing doses of megestrol acetate in the treatment of metastatic breast cancer, we conducted a phase I/II study among 57 patients. Three patients...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF01990033

    authors： Parnes HL,Abrams JS,Tchekmedyian NS,Tait N,Aisner J

    更新日期：1991-08-01 00:00:00

  • Recurrence and survival rates in British and Japanese women with breast cancer.

    abstract：:The biology of breast cancer in Japan appears to be changing in that, while post-menopausal Japanese patients have a better prognosis than comparable British women, no differences in recurrence or survival rates can now be found in pre-menopausal patients. ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF02633545

    authors： Allen DS,Bulbrook RD,Chaudary MA,Hayward JL,Yoshida M,Miura S,Murai JT

    更新日期：1991-05-01 00:00:00

  • Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG).

    abstract：:Addition of epirubicin to adjuvant chemotherapy can provide important benefits for patients with early breast cancer, but the optimal dose remains unclear. Further improvements can be achieved with dose-dense regimens, but densification of fluorouracil/epirubicin/cyclophosphamide (FEC) has proved difficult, with FEC(6...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-9894-7

    authors： Kahán Z,Spanik S,Wagnerova M,Skacel T,Planko B,Fitzthum E,Lindner E,Soldatenkova V,Zielinski CC,Brodowicz T

    更新日期：2008-12-01 00:00:00

  • A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation.

    abstract：PURPOSE:The Janus-associated kinase (JAK)/signal transducer and activator of transcription pathway is a key regulator of inflammatory signaling, associated with tumorigenesis, cell survival, and progression. This randomized phase 2 trial evaluated the efficacy and safety of the addition of ruxolitinib, a JAK1/JAK2 inhi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-018-4770-6

    authors： O'Shaughnessy J,DeMichele A,Ma CX,Richards P,Yardley DA,Wright GS,Kalinsky K,Steis R,Diab S,Kennealey G,Geschwindt R,Jiang W,Rugo HS

    更新日期：2018-08-01 00:00:00

  • FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.

    abstract：:FOXP3-expressing T regulatory lymphocytes (Tregs) have been described as putative mediators of immune tolerance, and thus facilitators of tumor growth. When found in association with various malignancies, Tregs are generally markers of poor clinical outcome. However, it is unknown whether they are also associated with...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2556-4

    authors： Lal A,Chan L,Devries S,Chin K,Scott GK,Benz CC,Chen YY,Waldman FM,Hwang ES

    更新日期：2013-06-01 00:00:00

  • Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma.

    abstract：:The ability of the antiangiogenic agents TNP-470 and minocycline, singly or in combination, to potentiate the antitumor effects of several cytotoxic therapies was assessed in the murine EMT-6 mammary carcinoma as well as in two drug resistant sublines of that tumor designated EMT-6/CTX and EMT-6/CDDP. The antiangiogen...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00666043

    authors： Teicher BA,Holden SA,Dupuis NP,Kakeji Y,Ikebe M,Emi Y,Goff D

    更新日期：1995-01-01 00:00:00

  • Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.

    abstract：:Cytoplasmic HuR is associated with reduced survival in invasive breast cancer. We designed this study to determine the predictive and prognostic value of HuR expression in women with breast cancer who underwent neoadjuvant chemotherapy followed by surgical resection. We immunohistochemically analyzed cytoplasmic HuR e...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2679-7

    authors： Wang J,Li D,Wang B,Wu Y

    更新日期：2013-09-01 00:00:00

  • The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome.

    abstract：BACKGROUND:Telomerase is a ribonucleoprotein enzyme that synthesises telomeres in human germ cells, embryogenesis and in cancer, maintaining chromosomal length, stability and cellular immortality. The hTERT gene is the rate-limiting determinant of telomerase reactivation during immortalization and malignant transformat...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9622-8

    authors： Salhab M,Jiang WG,Newbold RF,Mokbel K

    更新日期：2008-05-01 00:00:00

  • Larger axillary metastases in obese women and smokers with breast cancer--an influence by host factors on early tumor behavior.

    abstract：:To better define the influence by host factors on very early breast cancer behavior, we retrospectively analyzed nodal status, diameter of the largest axillary metastasis (M), diameter of the primary tumor (P), the M/P ratio, tumor estrogen receptor status, age, obesity, and smoking habits in 176 women with node-posit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00689833

    authors： Daniell HW,Tam E,Filice A

    更新日期：1993-01-01 00:00:00

  • The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

    abstract：BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9803-5

    authors： Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

    更新日期：2008-02-01 00:00:00

  • Clinical significance of angiogenic factors in breast cancer.

    abstract：:Growth, progression, and metastasis of breast cancer, as well as of most of the other tumors, are angiogenesis-dependent processes. Several pro-angiogenic growth factors and endogenous inhibitors of angiogenesis have been identified and sequenced, and experimental studies suggest that angiogenic activity of a tumor ma...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1006175504673

    authors： Locopo N,Fanelli M,Gasparini G

    更新日期：1998-01-01 00:00:00

  • Intracystic papillary carcinoma: clinical presentation, patterns of practice, and oncological outcomes.

    abstract：BACKGROUND:Intracystic/encapsulated papillary carcinoma remains a poorly understood disease of the breast with a little amount of reports that describe it. It shares features with DCIS and IDC and predominantly affects postmenopausal women. This study aims to evaluate the clinical presentation, treatment, and outcomes ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05680-9

    authors： Hassan Z,Boulos F,Abbas J,El Charif MH,Assi H,Sbaity E

    更新日期：2020-07-01 00:00:00

  • A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.

    abstract：:The aromatase inhibitors exemestane and anastrozole are approved in Japan for first-line treatment of postmenopausal patients with advanced, hormone-receptor-positive breast cancer. This phase 3, randomized, double-blind study directly compared time to progression (TTP) for exemestane and anastrozole therapy in this p...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-013-2573-3

    authors： Iwata H,Masuda N,Ohno S,Rai Y,Sato Y,Ohsumi S,Hashigaki S,Nishizawa Y,Hiraoka M,Morimoto T,Sasano H,Saeki T,Noguchi S

    更新日期：2013-06-01 00:00:00

  • Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables.

    abstract：AIMS:Rapamycin and its analogues are currently being tested in clinical trials as novel-targeted anticancer agents. Pre-clinical studies that used breast cancer cell lines have suggested that p-Akt or p-S6K1 expressing tumors, as well as PTEN negative tumors, were sensitive to rapamycin. The aims of this study were to ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9746-x

    authors： Noh WC,Kim YH,Kim MS,Koh JS,Kim HA,Moon NM,Paik NS

    更新日期：2008-08-01 00:00:00

  • Carotenoids and breast cancer risk: a meta-analysis and meta-regression.

    abstract：:The purpose of this article is to comprehensively summarize the associations between carotenoids and breast cancer and quantitatively estimate their dose-response relationships. We searched PubMed, Embase, and Cochrane databases (from January 1982 to 1 May 2011) and the references of the relevant articles in English w...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-011-1723-8

    authors： Hu F,Wang Yi B,Zhang W,Liang J,Lin C,Li D,Wang F,Pang D,Zhao Y

    更新日期：2012-01-01 00:00:00

  • PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.

    abstract：:It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical relevance of both predict...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2143-0

    authors： Prat A,Parker JS,Fan C,Perou CM

    更新日期：2012-08-01 00:00:00

  • Inhibition of cell proliferation by 17beta-estradiol and heregulin beta1 in estrogen receptor negative human breast carcinoma cell lines.

    abstract：:Heregulin (HRG) and 17beta-estradiol (E2) interactions that modulate growth of breast cancer cell lines have recently been demonstrated. We examined the ability of heregulin beta1 (HRGbeta1) and 17beta-estradiol to modulate the biological behavior of estrogen receptor (ER) negative human breast cancer cell lines (AU-5...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006035603635

    authors： Yoo JY,Lessor T,Hamburger AW

    更新日期：1998-09-01 00:00:00

  • Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.

    abstract：:Proliferation of both mouse and human breast cancer cells was inhibited by chlorpheniramine (CPA) in a dose-response manner. At the beginning of the exponential phase of growth (two days after seeding), 250 microM CPA was able to reduce cell proliferation by 75% (in Ehrlich cell cultures) and 30% (in MCF-7 cultures). ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00668208

    authors： Medina MA,García de Veas R,Morata P,Lozano J,Sánchez-Jiménez F

    更新日期：1995-08-01 00:00:00